The Congress " HUMAN AND MEDICINE " is one of the most important annual medical events in Ukraine, which is a unique platform for the exchange of experiences and the most important achievements in various fields of science and clinical practice based on evidence-based medicine.
Congress " HUMAN AND MEDICINE " - an interdisciplinary platform for training, education, constructive dialogue of scientists, practitioners and experts in various fields of medicine, which opens the possibility for participants to participate in numerous thematic lectures, workshops, symposia, with leading domestic and foreign speakers.
This year's online Congress " HUMAN AND MEDICINE " - DNIPRO is dedicated to the DIALOGUE OF THE PRIMARY DOCTOR AND THE NARROW SPECIALIST.
The congress reports presented the benefits of Artrida®, the only European injectable chondroitin sulfate in Ukraine. It was noted that the drug "Artrida®" is manufactured at the well-known French plant Haupt Pharma (France) according to European requirements of Good Manufacturing Practice (GMP), which definitely guarantees the quality, effectiveness and safety of the drug. The manufacturer of the substance of the drug Artrida® is one of the world leaders in the manufacture of highly purified drugs of cholesterol. Important issues regarding the difference in injecting drugs and its effect on treatment outcomes were addressed. Thus, the drug "Artrida®" is obtained from raw materials of cattle, which has a high degree of purification and is guaranteed to be free of purines. According to the authors of comparative international studies, the active substance of the drug "Artrida®" is safer than drugs based on porcine cholesterol, and has twice the long-acting fraction of cholesterol, which will certainly be reflected in excellent tolerability, potency and longer therapy.
The congress also highlighted new opportunities for central muscle relaxants in the treatment of back pain. One of the centrally acting muscle relaxants, which is widely used in the treatment of painful skeletal muscle spasms due to pathologies of the musculoskeletal system, is thiocolchicoside - Tionex. Tionex has significant therapeutic potential in the treatment of painful skeletal muscle spasms, due to its pharmacokinetic profile, which demonstrates its ability to rapidly reach therapeutic concentrations, have a significant muscle relaxant effect and minimize the manifestation of toxic effects. It was also noted at the congress that a comparative analysis of the pharmacokinetic parameters of injecting muscle relaxants with the active substance thiocolchicoside allows us to conclude that Tionex is highly equivalent to the original drug with advantages in efficacy and safety profile.